Kết quả điều trị bước 2 ung thư phổi không tế bào nhỏ có đột biến T790M thứ phát bằng osimertinib tại Bệnh viện ung bướu Đà Nẵng

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Mỹ Trang Lương, Thị Nhật Linh Lưu, Kim Thông Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học lâm sàng Bệnh viện Trung ương Huế, 2023

Mô tả vật lý:

Bộ sưu tập: Metadata

ID: 341347

Thêm vào giỏ Liên kết toàn văn

Mục tiêu: Đánh giá kết quả điều trị bước 2 ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến T790M thứ phát bằng Osimertinib. Đối tượng, phương pháp: Nghiên cứu mô tả hồi cứu kết hợp tiến cứu trên 22 bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến EGFR tiến triển sau điều trị EGFR-TKIs thế hệ 1,2, xuất hiện đột biến kháng thuốc thứ phát T790M được điều trị bằng Osimertinib tại bệnh viện Ung bướu Đà Nẵng từ tháng 03/2020 đến hết tháng 11/2022, theo dõi đến hết tháng 6/2023. Kết quả: Tỷ lệ đáp ứng khách quan của Osimertinib trong điều trị bước 2 là 72,7%, tỷ lệ kiểm soát bệnh là 86,4%. Trung vị thời gian sống thêm bệnh không tiến triển (PFS) là 10 tháng. Tác dụng không mong muốn thường gặp nhất khi điều trị bằng Osimertinib là ban da (36,4%), tiêu chảy (31,8%), khô da (22,7%), viêm quanh móng (18,2%), viêm niêm mạc miệng (13,6%). Phần lớn các tác dụng không mong muốn này ở mức độ nhẹ, không bệnh nhân nào phải giảm liều hay gián đoạn điều trị. Kết luận: Osimertinib có hiệu quả cao và an toàn trong điều trị bước 2 trong ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến T790M thứ phát. ABSTRACT Results of second - line treatment acquired T790M mutation non - small cell lung cancer with osimertinib at Danang Oncology Hospital Objectives: To evaluate the results of second - line treatment in stage IV non-small cell lung cancer patients who have acquired T790M mutation with Osimertinib. Methods: A cross - sectional descriptive study was conducted in 22 patients with EGFR mutation positive stage IV non - small cell lung cancer who failed after first - and second - generation EGFR - TKIs therapy with presence of acquired T790M resistance mutation, were treated with Osimertinib at Da Nang Oncology Hospital from March 2020 to the end of November 2022 and follow up until the end of June 2023. Results: The objective response rate of Osimertinib in second - line treatment was 72,7%, disease control rate was 85.4%, the median progression - free survival (PFS) was 10 months. The most common side effects of Osimertinib were rash (36.4%), diarrhea (31.8%), dry skin (22.7%), paronychia (18.2%), mucositis oral (13.6%). Most of side effects were mild, and no patient required a dose reduction or treatment interruption. Conclusion: Osimertinib is highly effective and safe in the second-line treatment of stage IV non - small cell lung cancer with acquired T790M mutation.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR